**Name of journal:** *World Journal of Gastroenterology*

**ESPS Manuscript NO: 29469**

**Manuscript Type:** **REVIEW**

**Updated therapeutic outcome for patients with periampullary and pancreatic cancer related to recent translational research**

Buanes TA. Outcome in periampullary and pancreatic cancer

Trond A Buanes

**Trond A Buanes,** Department of Hepato-Pancreatico-Biliary Surgery, Oslo University Hospital (OuS), N-0424 Oslo, Norway

**Trond A Buanes,** Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, N-0424 Oslo, Norway

**Author** **contributions**: Buanes TA solely contributed to this manuscript.

**Conflict-of-interest** **statement:** The author has no conflicts-of-interest.

**Correspondence to: Trond A Buanes, MD, PhD, Professor of Surgery**, Department of Hepato-Pancreatico-Biliary Surgery, Oslo University Hospital (OuS), Nydalen, N-0424 Oslo, Norway. trond.buanes@medisin.uio.no

**Telephone:** +47-2-3070958

**Fax:** +47-2-3072526

**Received:** August 15, 2016

**Peer-review started:** August 16, 2016

**First decision:** October 11, 2016

**Revised:** October 14, 2016

**Accepted:** November 23, 2016

**Article in press:**

**Published online:**

**Abstract**Chemotherapy with improved effect in patients with metastatic pancreatic cancer has recently been established, launching a new era for patients with this very aggressive disease. FOLFIRINOX and gemcitabine plus nab-paclitaxel are different regimens, both capable of stabilizing the disease, thus increasing the number of patients who can reach second line and even third line of treatment. Concurrently, new windows of opportunity open for nutritional support and other therapeutic interventions, improving quality of life. Also pancreatic surgery has changed significantly during the latest years. Extended operations, including vascular/multivisceral resections are frequently performed in specialized centers, pushing borders of resectability. Potentially curative treatment including neoadjuvant and adjuvant chemotherapy is offered new patient groups. Translational research is the basis for the essential understanding of the ongoing development. Even thou biomarkers for clinical management of patients with periampullary tumors have almost been lacking, biomarker driven trials are now in progress. New insight is constantly made available for clinicians; one recent example is selection of patients for gemcitabine treatment based on the expression level of the human equilibrium nucleoside transporter 1 (hENT1). An example of new diagnostic tools is identification of early pancreatic cancer patients by a three-biomarker panel in urine: The proteins LYVE-1, REG1A and TEF1. Requirement of treatment guideline revisions is intensifying, as combined chemotherapy regimens result in unexpected advantages. The ESPAC 4 trial outcome is an illustration: Addition of capecetabine in the adjuvant setting improved overall survival more than expected from the effect in advanced disease. Rapid implementation of new treatment options is mandatory when progress finally extends to patients with this serious disease.

**Key words:** Chemotherapy; Clinical outcome; Evidence-based medicine; Molecular expression profiling; Pancreatic cancer; Periampullary tumor; Prognostic markers; Survival

**© The Author(s) 2016.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** More effective chemotherapy and reorganized care for patients with periampullary carcinoma has opened windows of opportunity for improved surgical performance. Combined with neoadjuvant and adjuvant chemotherapy new patient groups can therefore be offered potentially curative treatment. A biomarkers can predict gemcitabine sensitivity (hENT-1), thus improving patient selection. A three-biomarker panel in urine can identify patients with early pancreatic adenocarcinoma. Clinical implementation of new diagnostic and therapeutic options is mandatory.

Buanes TA. Updated therapeutic outcome for patients with periampullary and pancreatic cancer related to recent translational research. *World J Gastroenterol* 2016; In press

**INTRODUCTION**

The different prognosis of pancreatic ductal adenocarcinoma (PDAC) and other periampullary carcinomas generates from profound biological diversities, increasingly explained by recent translational research[[1](#_ENREF_1)]. Most details from whole genome analysis of the mutational landscape[[2](#_ENREF_2)] generate knowledge that cannot be directly translated into clinical applications. Nevertheless, accumulative genetic and molecular biological information constantly increase the basis for clinical studies, and together with well-designed randomized controlled trials (RCT), the scientific development is accelerates. Outcome from recent trials are summarized in this review, related to relevant translational research which is rapidly generating new windows of diagnostic and therapeutic opportunity.

***Molecular expression profiling in histological subtypes***

The different prognosis for periampullary carcinomas, arising from pancreatic duct cells, distal bile duct cells or the mucosa of the ampulla or duodenum is documented by numerous authors[[3-6](#_ENREF_3)]. Intestinal or pancreaticobiliary differentiation have been shown to be prognostically more important than anatomic site of origin[[7](#_ENREF_7)], and an integrative platform, enabling profiling of micro(mi)RNA, mRNA and proteins have recently been published[[8](#_ENREF_8)]. Utilizing this platform, the molecular profiles of 85 periampullary adenocarcinomas, resected by pancreaticoduodenectomy (PD, or Whipple-procedure), was characterized by mRNA and miRNA expressions, comparing tumors from different anatomical sites of origin as well as different histological subtypes[[9](#_ENREF_9)]. Six miRNA families were downregulated and four were upregulated in the pancreaticobiliary type as compared to the intestinal type. miRNA and mRNAs associated with improved survival for both histopathological subtypes were identified. The genes PDPK1, PIK3R2, G6PC and miRNAs miR-127-3p and miR-377 were linked to enriched pathways and identified as prognostic markers for future clinical investigation.

In lung cancer patients a serum specific miRNA signature have been identified and validated in a study on 1115 high risk individuals for lung cancer, enrolled in a screening protocol. Overall accuracy, sensitivity and specificity were found above 70%, area under the curve (AUC) in the ROC-analysis was 0.85[[10](#_ENREF_10)]. In another report on circulating miRNA as biomarker of lung cancer, a panel of 24 miRNAs with optimal classification performance was identified[[11](#_ENREF_11)], enabling earlier detection of patients with lung cancer. Also in breast cancer circulating cell-free miRNAs have been found to be a biomarker for diagnostic and possibly targeted therapeutic utilization[[12](#_ENREF_12)]. A similar development is foreseeable for patients with periampullary tumors. A feasibility study on 46 patients with early stage PDAC, 29 patients with chronic pancreatitis and 26 healthy controls, investigated the discriminant ability of the combination of miR-143 and miR-30e in urine samples. Sensitivity above 80%, specificity above 90 % and AUC 0.923 in the ROC analysis was recently published[[13](#_ENREF_13)]. Also proteoms of 18 urine samples were analyzed in 192 patients with PDAC and 87 healthy controls. A three-biomarker panel was identified, able to differentiate patients with early stage pancreatic cancer from healthy controls by urine specimens[[14](#_ENREF_14)]. The discriminant ability of the proteins LYVE-1, REG1A and TEF1 increased further when combined with serum Ca19-9 value, resulting in AUC 0.97 in the ROC analysis. Accordingly, improved diagnosis of patients with localized i.e. resectable periampullary tumors is achievable, based on recent translational research. Epigenetic downregulation of miRNA 192 expression has recently been found to promote pancreatic cancer progression[[15](#_ENREF_15)], explaining the early metastatic behavior of PDAC. Thrombospondin-1 (TSP-1) was found to decrease preclinical, even 24 mo prior to the diagnosis of PDAC, and the combination of TSP-1 and serum Ca19-9 achieved significant diagnostic yield: AUC 0.86 in ROC analysis[[16](#_ENREF_16)]. A circulating miRNA profile has also been found to predict disease progression in patients with metastatic pancreatic cancer, receiving second line treatment[[17](#_ENREF_17)], illustrating that monitoring of treatment outcome is becoming possible, based on miRNA as biomarker.

**RESECTION MARGIN ASSESSMENT**

A standardized protocol for PD specimen examination, defining R1 status as tumor cells within 1 mm distance from the resection margin (RM), introduced by Verbeke[[18](#_ENREF_18)], have profoundly influenced reporting on R0/R1 status. This is illustrated by numerous reports, for example from the European Study Group for Pancreatic Cancer (ESPAC). In the ESPAC 1 study (inclusion 1994-2000), R1 status was reported in 18%[[19](#_ENREF_19)], ESPAC 3 (inclusion 2000-2008) reported R1 in 16%[[20](#_ENREF_20)], but in ESPAC 4 (inclusion 2009-2014) the frequency of R1 resections was 60%. Traditionally, R0 status was considered the only satisfactory outcome of PD[[21](#_ENREF_21)], as no clinical benefit was supposed to result from R1 resection. High rates of R0 status was conceived as an important indicator of good surgical performance. However, the ESPAC data and numerous other reports leave little doubt that historical differences in R1 rates result from divergence in pathology examination, more than quality of surgery[[22](#_ENREF_22)]. This opinion is supported by recent reports from the US[[23](#_ENREF_23)] and France[[24](#_ENREF_24)], underlining the importance of focused attention on standardized pathology reports in order to increase comparability of published data. In the center of Heidelberg, R0 status was not a prognostic indicator until the new standard was introduced[[25](#_ENREF_25)].
 Tumor growth is more dispersed in pancreatic head cancers than in rectal cancer, ampullary cancer and distal bile duct cancer[[26](#_ENREF_26)]. The implication is that even R0 status according to the standardized pathology protocol, does not completely exclude the possibility of residual tumor cells in the operation field. The necessity of adjuvant chemotherapy is very well documented, and is compatible with this hypothesis.

**MORPHOLOGICAL HETEROGENEITY**

High levels of morphological heterogeneity is common in PDAC[[27](#_ENREF_27)] and desmoplastic stroma is also predominant. Both characteristics are supposed to be obstacles to effective chemotherapeutic treatment. This hypothesis is supported by a report, classifying PDAC as classical, quasimesenchymal and exocrine-like with different therapeutic outcome[[28](#_ENREF_28)]. Genetic heterogeneity is contributing to therapeutic failure[[29](#_ENREF_29)], and whole-genome sequencing of 100 PDACs have recently redefined the mutational landscape[[2](#_ENREF_2)]. Further genome-wide investigation of copy number aberrations revealed significant prognostic implications. Deletion in the genes RAB12 and COLEC12 are associated with increased and amplification with decreased postoperative survival after PD[[30](#_ENREF_30)]. Also the stromal compartment provides stimulatory signals to the cancer cells, and the interaction has therapeutic relevance[[31](#_ENREF_31)]. Investigation of miRNA expression profiling of carcinomatous and stromal components in twenty periampullary adenocarcinomas, identified miRNA mediated interactions between carcinoma and stroma cells[[32](#_ENREF_32)] which may be utilized as future therapeutic targets. These data has potential for clinical utilization in the near future.

**PERSONALIZED MEDICINE – NEW CLINICALLY APPLICABLE BIOMARKERS**

Based on microarrays from patients randomized to chemotherapy in the ESPAC 3 trial plus controls from the ESPAC 1 trial, expression of the human equilibrium nucleoside transporter 1 (hENT1) levels were determined[[33](#_ENREF_33)]. Survival was compared between patients with high and low hENT1 expression in the gemcitabine and 5-FU arms. There was no difference in the 5 FU arm, whereas gemcitabine treated patients with high hENT 1 expression lived median 26.2 mo *vs* 17.1 months if hENT 1 expression was low (*P* = 0.002). Patients with Gemcitabine sensitive tumors can thus be selected, resulting in higher response rates in future, biomarker driven trials. There has recently been an explosion of available biomarkers for PDAC which need clinical validation[[34](#_ENREF_34),[35](#_ENREF_35)]. Exosomes are extracellular vesicles, containing proteins and nucleic acids, secreted by all cells, circulating in the blood. Identification of cancer cell derived exosomes has until recently not been possible, but a cell surface proteoglycan, glypican-1 (GPC1), specially enriched on cancer cell derived exosomes, was recently described, and GPC1 positive circulating exosomes (GPC1+crExos) were isolated from serum in PDAC-patients[[36](#_ENREF_36)]. Levels of GPC1+crExos were also found to correlate with tumor burden in the same patient series. Exosomes have even been shown to initiate pre-metastatic niche formation in the liver[[37](#_ENREF_37)], supporting the hypothesis proposed by Heiler *et al*[[38](#_ENREF_38)]that cancer stem cells gain the capacity for cell to cell crosstalk from generation, loading and delivery of exosomes. Utilization of exosomes as diagnostic biomarker as well as staging instrument is probably shortly upcoming opportunities.

**CHEMOTHERAPY**The development of effective oncological regimens has been slow, due to the chemoresistant character of PDAC. Table 1 shows key information from important clinical trials in first line therapy of metastatic disease, illustrating that gemcitabine became standard of care for fourteen years after Burris publication[[39](#_ENREF_39)]. Even though S1 (tegafur, prodrug of 5-FU) could increase response rate, overall survival (OS) was no longer[[40](#_ENREF_40)]. The addition of erlotinib to gemcitabine[[41](#_ENREF_41)] resulted in a significant but small increase in OS. FOLFIRINOX represented a breakthrough in 2011, increasing response rate x3, and median survival almost x2, from 6.8 mo in the gemcitabine group to 11.1 mo[[42](#_ENREF_42)]. In 2013 gemcitabine plus nab-paclitaxel was also shown to stabilize metastatic disease[[43](#_ENREF_43)]. This has opened new windows of opportunity for maintenance treatment in case of intolerable toxicity[[44](#_ENREF_44)], second line chemotherapy in cases of progression during first line treatment[[45-47](#_ENREF_45)] and even third line chemotherapy, even though no evidence for this is available yet. Regimen of second line chemotherapy should be chosen related to first line[[48](#_ENREF_48)]. Nanoliposomal irinotecan with 5-FU/FA increased OS to median 6.2 mo in a recently published RCT on gemcitabine refractory metastatic PDAC[[49](#_ENREF_49)]. The American Society of Clinical Oncology (ASCO) has recently published guidelines, incorporating this new insight, for treatment of patients with locally advanced[[50](#_ENREF_50)] and metastatic[[51](#_ENREF_51)] PDAC, recommending practical answers to key clinical questions for each patient group.
 Adjuvant chemotherapy has been evaluated in numerous RCTs, published during the last 15 years, as illustrated in Table 2. The necessity of adjuvant treatment was first documented by Neoptolemos in the ESPAC 1 trial[[19](#_ENREF_19),[52](#_ENREF_52)], later verified by Oettle[[53](#_ENREF_53)]. Medan and 5 year survival have increased during the following decennium. In a western patient population, gemcitabine plus capecitabine is now standard of care, resulting in median 28 mo and close to 30% five year survival after upfront surgery[[54](#_ENREF_54)]. A recent report from Japan[[55](#_ENREF_55)], suggests that even better outcome is achievable with adjuvant S1.

**SURGERY**The concept that upfront surgery is the best treatment option for patients with resectable tumors, is widely accepted[[1](#_ENREF_1),[56-58](#_ENREF_56)]. Nationwide centralization of PD in the Netherlands resulted in decreased postoperative in-hospital mortality from 9.8% in 2004 to 5.1% in 2009[[59](#_ENREF_59)], and the importance of volume-outcome relationship is increasingly emphasized[[60](#_ENREF_60)]. The reorganization of care for patients with periampullary cancer, based on multidisciplinary management, is widely supported[[48](#_ENREF_48),[61](#_ENREF_61)], and it has resulted in significant change in surgical practice during recent years. Extended operations including vascular/multivisceral resections are now frequently performed, and borders of resectability are continuously being pushed[[62](#_ENREF_62)]. The outcome value of multivisceral resections has been assessed[[63](#_ENREF_63)], criteria for clinical evaluations are defined[[64](#_ENREF_64)] and the basis for perfected surgical practice is continuously improving. Better handling of surgical complications is an important element of this development and a reason for reduced failure to rescue in case of serious complications[[65-67](#_ENREF_65)]. The improvement of outcome related to patient volume continues after 40 procedures/year at one hospital[[68](#_ENREF_68)]. Nevertheless, postoperative complications is a major problem after pancreatic surgery, precluding adjuvant chemotherapy and thus decreasing OS[[69](#_ENREF_69),[70](#_ENREF_70)]. The focus on improved surgical performance is therefore increasing, generating comprehensive evaluation of new technical details[[71](#_ENREF_71)].

Patients with borderline resectable PDAC was primarily described by Katz *et al*[[72](#_ENREF_72)] as those with localized disease with tumor or patients characteristics precluding immediate surgery. After neoadjuvant chemotherapy, chemoradiation or both in 125 of these patients, 66 (41%) underwent pancreatic resections, 18 (27%) with vascular resection/reconstruction. Median postoperative survival was 40 mo. Subsequently, the borderline concept is defined in detail[[73](#_ENREF_73)]. Management and treatment outcome in patients with borderline resectable tumors is an area of intense scrutiny.
 Neoadjuvant treatment, also in patients with resectable tumors, is widely accepted in the US[[74](#_ENREF_74),[75](#_ENREF_75)], whereas upfront surgery is still considered standard of care in influential European centers[[76](#_ENREF_76)]. Clinical and preclinical data support the concept that PDAC metastases appear early in the pathogenesis, even before the tumor can be identified[[77](#_ENREF_77)], favoring neoadjuvant chemotherapy. A meta-analysis focusing outcome in patients with resectable and unresectable tumors[[78](#_ENREF_78)], found that resection frequencies and survival after neoadjuvant therapy in resectable patients was similar to patients undergoing upfront surgery and adjuvant chemotherapy. In patients with unresectable tumors, approximately one third became resectable after restaging. In another meta-analysis of neoadjuvant chemotherapy in patients with borderline resectable PDAC, primary outcome measures were proportion of complete or partial response, stable or progressive disease as well as percentages of exploration and resection, and these results were also similar[[79](#_ENREF_79)]. This evidence seems to support recommendation of neoadjuvant chemotherapy in borderline resectable PDAC, as resection rates and survival can be raised to the same level as patients with resectable tumors. A report from the National Cancer Data base on patients with PDAC stage I and II, who underwent PD between 2006 and 2012[[80](#_ENREF_80)], found increased rates of neoadjuvant treatment from 12.0% in 2006 to 20.2% in 2012. Patients who complete all intended neoadjuvant therapy, including surgery and adjuvant chemotherapy are by some authors supposed to experience increases OS, compared to patients undergoing upfront surgery[[81](#_ENREF_81)]. However, evidence from well conducted RCTs is lacking, and the putative benefit of neoadjuvant treatment can be a by-product of selection bias, as patients with rapid disease progression never undergo surgery. Therefore, the real benefit or harm of neoadjuvant chemotherapy in patients with resectable PDAC still requires systematic evaluation. The International Study Group for Pancreatic Cancer (ISGPC) recommendations is still upfront surgery for resectable and borderline resectable tumors[[64](#_ENREF_64), [82](#_ENREF_82), [83](#_ENREF_83)].

**DISTAL CHOLANGIOCARCINOMA, AMPULLARY AND DUODENAL ADENOCARCINOMA**Patients with periampullary adenocarcinomas undergo the same surgical resectional procedure as patients with PDAC, and postoperative survival is longer[[84-88](#_ENREF_84)]. However, some data are contradictory: similar survival for patients with distal cholangiocarcinoma and PDAC was recently reported[[89](#_ENREF_89)], as well as comparable prognosis for ampullary and extra-ampullary duodenal carcinomas[[90](#_ENREF_90)]. Even ampullary carcinoma with the same median postoperative survival as PDAC has been described from Denmark[[91](#_ENREF_91)]. Routine histopathology from 207 PD specimens were recently re-evaluated by two independent experienced pancreatic pathologists, and 53% of distal cholangiocarcinoma were misdiagnosed as PDAC[[92](#_ENREF_92)]. A comprehensive assessment of tumor origin in pancreatic head cancer documented inaccurate and inconsistent distinctions between pancreatic, ampullary and distal bile duct cancer[[6](#_ENREF_6)]. This divergence in pathology assessment may explain some of the contradictory data on prognosis in periampullary carcinomas. Ampullary carcinoma can be of pancreaticobiliary- or intestinal type, and the molecular signatures of mRNA and miRNA, linked to specific intracellular pathways, correlate to subtype above anatomical origin in periampullary tumors[[9](#_ENREF_9)]. Histological subtype is a predictor of survival, and have also recently been found to influence response to adjuvant gemcitabine[[93](#_ENREF_93)].

**IS ADJUVANT CHEMOTHERAPY INDICATED FOR PERIAMPULLARY CARCINOMA?**A single center study from Johns Hopkins Hospital found that adjuvant chemoradiation did not improve survival[[94](#_ENREF_94)]. The only well conducted RCT, investigating this question, is the ESPAC 3 trial, in which 297 patients with ampullary carcinoma, 96 with distal cholangiocarcinoma and 35 other carcinoma were randomized between 5-FU/FA, Gemcitabine or observation only. Median survival was 35.2 mo in the observation group *vs* 43.1 mo in the two chemotherapy groups, but the difference was not significant in the primary analysis. After multivariate analysis, adjusting for prognostic variables, statistically significant survival benefit was found after adjuvant chemotherapy[[95](#_ENREF_95)]. The authors underline that distal cholangiocarcinoma should be analyzed separately, *i.e*., not together with tumors with other sites of origin, as periampullary adenocarcinoma is not a separate tumor entity. As documented above[[9](#_ENREF_9)], site of tumor origin influence expected survival and pancreaticobiliary and intestinal subtypes respond differently to adjuvant gemcitabine[[93](#_ENREF_93)]. Accordingly, the probable survival benefit from adjuvant chemotherapy, shown in the ESPAC 3 trial, should be further investigated by evaluation of combination chemotherapies in a modified study design.

**CONCLUSION**

Lack of biomarkers, applicable as diagnostic tools and/or therapeutic targets has been a major hindrance for development of personalized treatment in patients with periampullary tumors. This is now rapidly changing[[1](#_ENREF_1),[96](#_ENREF_96)]. A practical example is selection of patients for gemcitabine treatment guided by hENT1 expression[[33](#_ENREF_33)]. Clinical implementation of new micromolecular markers is presently a major issue. Subsequently, treatment guidelines need revision. Surgical treatment of metastatic PDAC has been evaluated[[97](#_ENREF_97)], resulting in median postoperative survival 13.8 mo, estimated one year survival 58.9%. In an earlier study of 40 patients with metastases from periampullary carcinoma undergoing curative intent surgery, median survival for the pancreaticobiliary subtype was 13 mo, intestinal 23 mo[[98](#_ENREF_98)]. Metastatic disease is therefore conceived as a palliative condition, without clinical benefit from resectional surgery[[58](#_ENREF_58)]. However, in a recent report from Milan[[99](#_ENREF_99)], 127 patients with metastatic PDAC were treated by the new chemotherapeutic regimens, and 11 patients with radiological and biochemical response (Ca19-9 normalization) underwent resection of the pancreatic primary tumor plus liver or lung metastases. Postoperative median survival was 39 mo *vs* 12 mo for the 116 patients without surgical resection. One year and three year survival were 100% *vs* 42% and 57% *vs* 5% respectively. The difference is obviously caused by better chemoresponse in the resected group, possibly also by additional benefit from resectional surgery. When new biomarkers enable personalized chemotherapeutic treatment and selection of patients for surgery based on improved knowledge about the malignancy potential of the tumor, cure seems achievable also for some patients with metastatic PDAC in the near future. Clarification of the role of surgery, related to chemotherapy is associated with severe methodological difficulties, as numerous patients deny inclusion in randomized trials, evaluating neoadjuvant chemotherapy. Low response rates of neoadjuvance and corresponding high risk of ending up with unresectable tumors are frequent patient concerns. These issues goes beyond the scope of this paper, but solid evidence, clarifying benefit/harm of neoadjuvant chemotherapy in pancreatic cancer will be major future scientific achievements.
 A major problem for numerous patients with periampullary carcinoma is that they suffer severely during most of their residual lifetime, and palliative interventions, improving their quality of life, are important. Appropriate instruments for measuring patient reported outcome (PRO) has been lacking, but a brief, disease specific instrument has recently been developed, the PAncreatic CAncer DIsease (PACADI) score[[100](#_ENREF_100)]. This is a brief, eight item, patient derived instrument, feasible also for patients with severe fatigue during late disease course. The future holds opportunities of well-designed interventional outcome-studies with survival and PRO as endpoints, increasing the rate of therapeutic intervention improvement.

**REFERENCES**

1 **Kleeff J**, Korc M, Apte M, La Vecchia C, Johnson CD, Biankin AV, Neale RE, Tempero M, Tuveson DA, Hruban RH, Neoptolemos JP. Pancreatic cancer. *Nat Rev Dis Primers* 2016; **2**: 16022 [PMID: 27158978 DOI: 10.1038/nrdp.2016.22]

2 **Waddell N**, Pajic M, Patch AM, Chang DK, Kassahn KS, Bailey P, Johns AL, Miller D, Nones K, Quek K, Quinn MC, Robertson AJ, Fadlullah MZ, Bruxner TJ, Christ AN, Harliwong I, Idrisoglu S, Manning S, Nourse C, Nourbakhsh E, Wani S, Wilson PJ, Markham E, Cloonan N, Anderson MJ, Fink JL, Holmes O, Kazakoff SH, Leonard C, Newell F, Poudel B, Song S, Taylor D, Waddell N, Wood S, Xu Q, Wu J, Pinese M, Cowley MJ, Lee HC, Jones MD, Nagrial AM, Humphris J, Chantrill LA, Chin V, Steinmann AM, Mawson A, Humphrey ES, Colvin EK, Chou A, Scarlett CJ, Pinho AV, Giry-Laterriere M, Rooman I, Samra JS, Kench JG, Pettitt JA, Merrett ND, Toon C, Epari K, Nguyen NQ, Barbour A, Zeps N, Jamieson NB, Graham JS, Niclou SP, Bjerkvig R, Grützmann R, Aust D, Hruban RH, Maitra A, Iacobuzio-Donahue CA, Wolfgang CL, Morgan RA, Lawlor RT, Corbo V, Bassi C, Falconi M, Zamboni G, Tortora G, Tempero MA, Gill AJ, Eshleman JR, Pilarsky C, Scarpa A, Musgrove EA, Pearson JV, Biankin AV, Grimmond SM. Whole genomes redefine the mutational landscape of pancreatic cancer. *Nature*2015; **518**: 495-501 [PMID: 25719666 DOI: 10.1038/nature14169]

3 **Nordby T**, Ikdahl T, Lothe IM, Ånonsen K, Hauge T, Edwin B, Line PD, Labori KJ, Buanes T. Opportunities of improvement in the management of pancreatic and periampullary tumors. *Scand J Gastroenterol* 2013; **48**: 617-625 [PMID: 23597153 DOI: 10.3109/00365521.2013.781218]

4 **Winter JM**, Cameron JL, Lillemoe KD, Campbell KA, Chang D, Riall TS, Coleman J, Sauter PK, Canto M, Hruban RH, Schulick RD, Choti MA, Yeo CJ. Periampullary and pancreatic incidentaloma: a single institution's experience with an increasingly common diagnosis. *Ann Surg* 2006; **243**: 673-80; discussion 680-3 [PMID: 16633003 DOI: 10.1097/01.sla.0000216763.27673.97]

5 **van Rijssen LB**, van der Geest LG, Bollen TL, Bruno MJ, van der Gaast A, Veerbeek L, Ten Kate FJ, Busch OR. National compliance to an evidence-based multidisciplinary guideline on pancreatic and periampullary carcinoma. *Pancreatology* 2015; **16**: 133-137 [PMID: 26560441 DOI: 10.1016/j.pan.2015.10.002]

6 **Verbeke CS**, Gladhaug IP. Resection margin involvement and tumour origin in pancreatic head cancer. *Br J Surg* 2012; **99**: 1036-1049 [PMID: 22517199 DOI: 10.1002/bjs.8734]

7 **Westgaard A**, Tafjord S, Farstad IN, Cvancarova M, Eide TJ, Mathisen O, Clausen OP, Gladhaug IP. Resectable adenocarcinomas in the pancreatic head: the retroperitoneal resection margin is an independent prognostic factor. *BMC Cancer* 2008; **8**: 5 [PMID: 18194510 DOI: 10.1186/1471-2407-8-5]

8 **Thomas JK**, Kim MS, Balakrishnan L, Nanjappa V, Raju R, Marimuthu A, Radhakrishnan A, Muthusamy B, Khan AA, Sakamuri S, Tankala SG, Singal M, Nair B, Sirdeshmukh R, Chatterjee A, Prasad TS, Maitra A, Gowda H, Hruban RH, Pandey A. Pancreatic Cancer Database: an integrative resource for pancreatic cancer. *Cancer Biol Ther* 2014; **15**: 963-967 [PMID: 24839966 DOI: 10.4161/cbt.29188]

9 **Sandhu V**, Bowitz Lothe IM, Labori KJ, Lingjærde OC, Buanes T, Dalsgaard AM, Skrede ML, Hamfjord J, Haaland T, Eide TJ, Børresen-Dale AL, Ikdahl T, Kure EH. Molecular signatures of mRNAs and miRNAs as prognostic biomarkers in pancreatobiliary and intestinal types of periampullary adenocarcinomas. *Mol Oncol* 2015; **9**: 758-771 [PMID: 25579086 DOI: 10.1016/j.molonc.2014.12.002]

10 **Montani F**, Marzi MJ, Dezi F, Dama E, Carletti RM, Bonizzi G, Bertolotti R, Bellomi M, Rampinelli C, Maisonneuve P, Spaggiari L, Veronesi G, Nicassio F, Di Fiore PP, Bianchi F. miR-Test: a blood test for lung cancer early detection. *J Natl Cancer Inst* 2015; **107**: djv063 [PMID: 25794889 DOI: 10.1093/jnci/djv063]

11 **Wozniak MB**, Scelo G, Muller DC, Mukeria A, Zaridze D, Brennan P. Circulating MicroRNAs as Non-Invasive Biomarkers for Early Detection of Non-Small-Cell Lung Cancer. *PLoS One* 2015; **10**: e0125026 [PMID: 25965386 DOI: 10.1371/journal.pone.0125026]

12 **Shin VY**, Siu JM, Cheuk I, Ng EK, Kwong A. Circulating cell-free miRNAs as biomarker for triple-negative breast cancer. *Br J Cancer* 2015; **112**: 1751-1759 [PMID: 25906045 DOI: 10.1038/bjc.2015.143]

13 **Debernardi S**, Massat NJ, Radon TP, Sangaralingam A, Banissi A, Ennis DP, Dowe T, Chelala C, Pereira SP, Kocher HM, Young BD, Bond-Smith G, Hutchins R, Crnogorac-Jurcevic T. Noninvasive urinary miRNA biomarkers for early detection of pancreatic adenocarcinoma. *Am J Cancer Res* 2015; **5**: 3455-3466 [PMID: 26807325]

14 **Radon TP**, Massat NJ, Jones R, Alrawashdeh W, Dumartin L, Ennis D, Duffy SW, Kocher HM, Pereira SP, Guarner posthumous L, Murta-Nascimento C, Real FX, Malats N, Neoptolemos J, Costello E, Greenhalf W, Lemoine NR, Crnogorac-Jurcevic T. Identification of a Three-Biomarker Panel in Urine for Early Detection of Pancreatic Adenocarcinoma. *Clin Cancer Res* 2015; **21**: 3512-3521 [PMID: 26240291 DOI: 10.1158/1078-0432.ccr-14-2467]

15 **Botla SK**, Savant S, Jandaghi P, Bauer AS, Mücke O, Moskalev EA, Neoptolemos JP, Costello E, Greenhalf W, Scarpa A, Gaida MM, Büchler MW, Strobel O, Hackert T, Giese NA, Augustin HG, Hoheisel JD. Early Epigenetic Downregulation of microRNA-192 Expression Promotes Pancreatic Cancer Progression. *Cancer Res* 2016; **76**: 4149-4159 [PMID: 27216198 DOI: 10.1158/0008-5472.can-15-0390]

16 **Jenkinson C**, Elliott VL, Evans A, Oldfield L, Jenkins RE, O'Brien DP, Apostolidou S, Gentry-Maharaj A, Fourkala EO, Jacobs IJ, Menon U, Cox T, Campbell F, Pereira SP, Tuveson DA, Park BK, Greenhalf W, Sutton R, Timms JF, Neoptolemos JP, Costello E. Decreased Serum Thrombospondin-1 Levels in Pancreatic Cancer Patients Up to 24 Months Prior to Clinical Diagnosis: Association with Diabetes Mellitus. *Clin Cancer Res* 2016; **22**: 1734-1743 [PMID: 26573598 DOI: 10.1158/1078-0432.ccr-15-0879]

17 **Tian X**, Shivapurkar N, Wu Z, Hwang JJ, Pishvaian MJ, Weiner LM, Ley L, Zhou D, Zhi X, Wellstein A, Marshall JL, He AR. Circulating microRNA profile predicts disease progression in patients receiving second-line treatment of lapatinib and capecitabine for metastatic pancreatic cancer. *Oncol Lett* 2016; **11**: 1645-1650 [PMID: 26998056 DOI: 10.3892/ol.2016.4101]

18 **Verbeke CS**, Leitch D, Menon KV, McMahon MJ, Guillou PJ, Anthoney A. Redefining the R1 resection in pancreatic cancer. *Br J Surg* 2006; **93**: 1232-1237 [PMID: 16804874 DOI: 10.1002/bjs.5397]

19 **Neoptolemos JP**, Stocken DD, Friess H, Bassi C, Dunn JA, Hickey H, Beger H, Fernandez-Cruz L, Dervenis C, Lacaine F, Falconi M, Pederzoli P, Pap A, Spooner D, Kerr DJ, Büchler MW. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. *N Engl J Med* 2004; **350**: 1200-1210 [PMID: 15028824 DOI: 10.1056/NEJMoa032295]

20 **Neoptolemos JP**, Stocken DD, Bassi C, Ghaneh P, Cunningham D, Goldstein D, Padbury R, Moore MJ, Gallinger S, Mariette C, Wente MN, Izbicki JR, Friess H, Lerch MM, Dervenis C, Oláh A, Butturini G, Doi R, Lind PA, Smith D, Valle JW, Palmer DH, Buckels JA, Thompson J, McKay CJ, Rawcliffe CL, Büchler MW. Adjuvant chemotherapy with fluorouracil plus folinic acid *vs* gemcitabine following pancreatic cancer resection: a randomized controlled trial. *JAMA* 2010; **304**: 1073-1081 [PMID: 20823433 DOI: 10.1001/jama.2010.1275]

21 **Evans DB**, Farnell MB, Lillemoe KD, Vollmer C, Strasberg SM, Schulick RD. Surgical treatment of resectable and borderline resectable pancreas cancer: expert consensus statement. *Ann Surg Oncol* 2009; **16**: 1736-1744 [PMID: 19387741 DOI: 10.1245/s10434-009-0416-6]

22 **Verbeke CS**. Resection margins in pancreatic cancer: are we entering a new era? *HPB (Oxford)* 2014; **16**: 1-2 [PMID: 24329942 DOI: 10.1111/hpb.12122]

23 **Gnerlich JL**, Luka SR, Deshpande AD, Dubray BJ, Weir JS, Carpenter DH, Brunt EM, Strasberg SM, Hawkins WG, Linehan DC. Microscopic margins and patterns of treatment failure in resected pancreatic adenocarcinoma. *Arch Surg* 2012; **147**: 753-760 [PMID: 22911074 DOI: 10.1001/archsurg.2012.1126]

24 **Delpero JR**, Bachellier P, Regenet N, Le Treut YP, Paye F, Carrere N, Sauvanet A, Autret A, Turrini O, Monges-Ranchin G, Boher JM. Pancreaticoduodenectomy for pancreatic ductal adenocarcinoma: a French multicentre prospective evaluation of resection margins in 150 evaluable specimens. *HPB (Oxford)* 2014; **16**: 20-33 [PMID: 23464850 DOI: 10.1111/hpb.12061]

25 **Hartwig W**, Hackert T, Hinz U, Gluth A, Bergmann F, Strobel O, Büchler MW, Werner J. Pancreatic cancer surgery in the new millennium: better prediction of outcome. *Ann Surg* 2011; **254**: 311-319 [PMID: 21606835 DOI: 10.1097/SLA.0b013e31821fd334]

26 **Verbeke CS**, Knapp J, Gladhaug IP. Tumour growth is more dispersed in pancreatic head cancers than in rectal cancer: implications for resection margin assessment. *Histopathology* 2011; **59**: 1111-1121 [PMID: 22175891 DOI: 10.1111/j.1365-2559.2011.04056.x]

27 **Verbeke C**. Morphological heterogeneity in ductal adenocarcinoma of the pancreas - Does it matter? *Pancreatology* 2016; **16**: 295-301 [PMID: 26924665 DOI: 10.1016/j.pan.2016.02.004]

28 **Collisson EA**, Sadanandam A, Olson P, Gibb WJ, Truitt M, Gu S, Cooc J, Weinkle J, Kim GE, Jakkula L, Feiler HS, Ko AH, Olshen AB, Danenberg KL, Tempero MA, Spellman PT, Hanahan D, Gray JW. Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy. *Nat Med* 2011; **17**: 500-503 [PMID: 21460848 DOI: 10.1038/nm.2344]

29 **Burrell RA**, Swanton C. Tumour heterogeneity and the evolution of polyclonal drug resistance. *Mol Oncol* 2014; **8**: 1095-1111 [PMID: 25087573 DOI: 10.1016/j.molonc.2014.06.005]

30 **Sandhu V**, Wedge DC, Bowitz Lothe IM, Labori KJ, Dentro SC, Buanes T, Skrede ML, Dalsgaard AM, Munthe E, Myklebost O, Lingjærde OC, Børresen-Dale AL, Ikdahl T, Van Loo P, Nord S, Kure EH. The Genomic Landscape of Pancreatic and Periampullary Adenocarcinoma. *Cancer Res* 2016; **76**: 5092-5102 [PMID: 27488532 DOI: 10.1158/0008-5472.can-16-0658]

31 **Whatcott C**, Han H, Posner RG, Von Hoff DD. Tumor-stromal interactions in pancreatic cancer. *Crit Rev Oncog* 2013; **18**: 135-151 [PMID: 23237556]

32 **Sandhu V**, Bowitz Lothe IM, Labori KJ, Skrede ML, Hamfjord J, Dalsgaard AM, Buanes T, Dube G, Kale MM, Sawant S, Kulkarni-Kale U, Børresen-Dale AL, Lingjærde OC, Kure EH. Differential expression of miRNAs in pancreatobiliary type of periampullary adenocarcinoma and its associated stroma. *Mol Oncol* 2016; **10**: 303-316 [PMID: 26590090 DOI: 10.1016/j.molonc.2015.10.011]

33 **Greenhalf W**, Ghaneh P, Neoptolemos JP, Palmer DH, Cox TF, Lamb RF, Garner E, Campbell F, Mackey JR, Costello E, Moore MJ, Valle JW, McDonald AC, Carter R, Tebbutt NC, Goldstein D, Shannon J, Dervenis C, Glimelius B, Deakin M, Charnley RM, Lacaine F, Scarfe AG, Middleton MR, Anthoney A, Halloran CM, Mayerle J, Oláh A, Jackson R, Rawcliffe CL, Scarpa A, Bassi C, Büchler MW. Pancreatic cancer hENT1 expression and survival from gemcitabine in patients from the ESPAC-3 trial. *J Natl Cancer Inst* 2014; **106**: djt347 [PMID: 24301456 DOI: 10.1093/jnci/djt347]

34 **Verma M**. Pancreatic cancer biomarkers and their implication in cancer diagnosis and epidemiology. *Cancers (Basel)* 2010; **2**: 1830-1837 [PMID: 24281203 DOI: 10.3390/cancers2041830]

35 **Harsha HC**, Kandasamy K, Ranganathan P, Rani S, Ramabadran S, Gollapudi S, Balakrishnan L, Dwivedi SB, Telikicherla D, Selvan LD, Goel R, Mathivanan S, Marimuthu A, Kashyap M, Vizza RF, Mayer RJ, Decaprio JA, Srivastava S, Hanash SM, Hruban RH, Pandey A. A compendium of potential biomarkers of pancreatic cancer. *PLoS Med* 2009; **6**: e1000046 [PMID: 19360088 DOI: 10.1371/journal.pmed.1000046]

36 **Melo SA**, Luecke LB, Kahlert C, Fernandez AF, Gammon ST, Kaye J, LeBleu *VS*, Mittendorf EA, Weitz J, Rahbari N, Reissfelder C, Pilarsky C, Fraga MF, Piwnica-Worms D, Kalluri R. Glypican-1 identifies cancer exosomes and detects early pancreatic cancer. *Nature* 2015; **523**: 177-182 [PMID: 26106858 DOI: 10.1038/nature14581]

37 **Costa-Silva B**, Aiello NM, Ocean AJ, Singh S, Zhang H, Thakur BK, Becker A, Hoshino A, Mark MT, Molina H, Xiang J, Zhang T, Theilen TM, García-Santos G, Williams C, Ararso Y, Huang Y, Rodrigues G, Shen TL, Labori KJ, Lothe IM, Kure EH, Hernandez J, Doussot A, Ebbesen SH, Grandgenett PM, Hollingsworth MA, Jain M, Mallya K, Batra SK, Jarnagin WR, Schwartz RE, Matei I, Peinado H, Stanger BZ, Bromberg J, Lyden D. Pancreatic cancer exosomes initiate pre-metastatic niche formation in the liver. *Nat Cell Biol* 2015; **17**: 816-826 [PMID: 25985394 DOI: 10.1038/ncb3169]

38 **Heiler S**, Wang Z, Zöller M. Pancreatic cancer stem cell markers and exosomes - the incentive push. *World J Gastroenterol* 2016; **22**: 5971-6007 [PMID: 27468191 DOI: 10.3748/wjg.v22.i26.5971]

39 **Burris HA**, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, Cripps MC, Portenoy RK, Storniolo AM, Tarassoff P, Nelson R, Dorr FA, Stephens CD, Von Hoff DD. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. *J Clin Oncol* 1997; **15**: 2403-2413 [PMID: 9196156]

40 **Ueno H**, Okusaka T, Ikeda M, Takezako Y, Morizane C. An early phase II study of S-1 in patients with metastatic pancreatic cancer. *Oncology* 2005; **68**: 171-178 [PMID: 16006754 DOI: 10.1159/000086771]

41 **Moore MJ**, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S, Au HJ, Murawa P, Walde D, Wolff RA, Campos D, Lim R, Ding K, Clark G, Voskoglou-Nomikos T, Ptasynski M, Parulekar W. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. *J Clin Oncol* 2007; **25**: 1960-1966 [PMID: 17452677 DOI: 10.1200/jco.2006.07.9525]

42 **Conroy T**, Desseigne F, Ychou M, Bouché O, Guimbaud R, Bécouarn Y, Adenis A, Raoul JL, Gourgou-Bourgade S, de la Fouchardière C, Bennouna J, Bachet JB, Khemissa-Akouz F, Péré-Vergé D, Delbaldo C, Assenat E, Chauffert B, Michel P, Montoto-Grillot C, Ducreux M. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. *N Engl J Med* 2011; **364**: 1817-1825 [PMID: 21561347 DOI: 10.1056/NEJMoa1011923]

43 **Von Hoff DD**, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, Seay T, Tjulandin SA, Ma WW, Saleh MN, Harris M, Reni M, Dowden S, Laheru D, Bahary N, Ramanathan RK, Tabernero J, Hidalgo M, Goldstein D, Van Cutsem E, Wei X, Iglesias J, Renschler MF. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. *N Engl J Med* 2013; **369**: 1691-1703 [PMID: 24131140 DOI: 10.1056/NEJMoa1304369]

44 **Reni M**, Cereda S, Milella M, Novarino A, Passardi A, Mambrini A, Di Lucca G, Aprile G, Belli C, Danova M, Bergamo F, Franceschi E, Fugazza C, Ceraulo D, Villa E. Maintenance sunitinib or observation in metastatic pancreatic adenocarcinoma: a phase II randomised trial. *Eur J Cancer* 2013; **49**: 3609-3615 [PMID: 23899530 DOI: 10.1016/j.ejca.2013.06.041]

45 **Caparello C**, Vivaldi C, Fornaro L, Musettini G, Pasquini G, Catanese S, Masi G, Lencioni M, Falcone A, Vasile E. Second-line therapy for advanced pancreatic cancer: evaluation of prognostic factors and review of current literature. *Future Oncol* 2016; **12**: 901-908 [PMID: 26883177 DOI: 10.2217/fon.16.16]

46 **Oettle H**, Riess H, Stieler JM, Heil G, Schwaner I, Seraphin J, Görner M, Mölle M, Greten TF, Lakner V, Bischoff S, Sinn M, Dörken B, Pelzer U. Second-line oxaliplatin, folinic acid, and fluorouracil versus folinic acid and fluorouracil alone for gemcitabine-refractory pancreatic cancer: outcomes from the CONKO-003 trial. *J Clin Oncol* 2014; **32**: 2423-2429 [PMID: 24982456 DOI: 10.1200/jco.2013.53.6995]

47 **Pelzer U**, Schwaner I, Stieler J, Adler M, Seraphin J, Dörken B, Riess H, Oettle H. Best supportive care (BSC) versus oxaliplatin, folinic acid and 5-fluorouracil (OFF) plus BSC in patients for second-line advanced pancreatic cancer: a phase III-study from the German CONKO-study group. *Eur J Cancer* 2011; **47**: 1676-1681 [PMID: 21565490 DOI: 10.1016/j.ejca.2011.04.011]

48 **Takaori K**, Bassi C, Biankin A, Brunner TB, Cataldo I, Campbell F, Cunningham D, Falconi M, Frampton AE, Furuse J, Giovannini M, Jackson R, Nakamura A, Nealon W, Neoptolemos JP, Real FX, Scarpa A, Sclafani F, Windsor JA, Yamaguchi K, Wolfgang C, Johnson CD. International Association of Pancreatology (IAP)/European Pancreatic Club (EPC) consensus review of guidelines for the treatment of pancreatic cancer. *Pancreatology* 2016; **16**: 14-27 [PMID: 26699808 DOI: 10.1016/j.pan.2015.10.013]

49 **Wang-Gillam A**, Li CP, Bodoky G, Dean A, Shan YS, Jameson G, Macarulla T, Lee KH, Cunningham D, Blanc JF, Hubner RA, Chiu CF, Schwartsmann G, Siveke JT, Braiteh F, Moyo V, Belanger B, Dhindsa N, Bayever E, Von Hoff DD, Chen LT. Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial. *Lancet* 2016; **387**: 545-557 [PMID: 26615328 DOI: 10.1016/s0140-6736(15)00986-1]

50 **Balaban EP**, Mangu PB, Khorana AA, Shah MA, Mukherjee S, Crane CH, Javle MM, Eads JR, Allen P, Ko AH, Engebretson A, Herman JM, Strickler JH, Benson AB, Urba S, Yee NS. Locally Advanced, Unresectable Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline. *J Clin Oncol* 2016; **34**: 2654-2668 [PMID: 27247216 DOI: 10.1200/jco.2016.67.5561]

51 **Sohal DP**, Mangu PB, Khorana AA, Shah MA, Philip PA, O'Reilly EM, Uronis HE, Ramanathan RK, Crane CH, Engebretson A, Ruggiero JT, Copur MS, Lau M, Urba S, Laheru D. Metastatic Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline. *J Clin Oncol* 2016; **34**: 2784-2796 [PMID: 27247222 DOI: 10.1200/jco.2016.67.1412]

52 **Neoptolemos JP**, Dunn JA, Stocken DD, Almond J, Link K, Beger H, Bassi C, Falconi M, Pederzoli P, Dervenis C, Fernandez-Cruz L, Lacaine F, Pap A, Spooner D, Kerr DJ, Friess H, Büchler MW. Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trial. *Lancet* 2001; **358**: 1576-1585 [PMID: 11716884]

53 **Oettle H**, Post S, Neuhaus P, Gellert K, Langrehr J, Ridwelski K, Schramm H, Fahlke J, Zuelke C, Burkart C, Gutberlet K, Kettner E, Schmalenberg H, Weigang-Koehler K, Bechstein WO, Niedergethmann M, Schmidt-Wolf I, Roll L, Doerken B, Riess H. Adjuvant chemotherapy with gemcitabine *vs* observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. *JAMA* 2007; **297**: 267-277 [PMID: 17227978 DOI: 10.1001/jama.297.3.267]

54 **Neoptolemos J**, Palmer D, Ghaneh P, Valle JW, Cunningham D, Wadsley J, Meyer T, Anthoney A, Glimelius B, Lind P, Falk S, Izbicki J, Middleton G, Ross P, Wasan H, McDonald A, Crosby T, Psarelli E, Hammel P, Büchler M. ESPAC-4: A multicenter, international, open label randomized controlled phase III trail og adjuvant combination chemotherapy of gemacitabine (GEM) and capecitabine (CAP), versus monotherapy gemcitamine in patients with resected pancreatic ducal ademocarcinoma. Proceedings of the ASCO Annual Meeting; 2016 Jun 6-16; Chicago, USA. Abstract No: LBA4006. Available from: URL: [http://meetinglibraryascoorg/content/122648?media=vm](http://meetinglibraryascoorg/content/122648?media=vm;)

55 **Uesaka K**, Boku N, Fukutomi A, Okamura Y, Konishi M, Matsumoto I, Kaneoka Y, Shimizu Y, Nakamori S, Sakamoto H, Morinaga S, Kainuma O, Imai K, Sata N, Hishinuma S, Ojima H, Yamaguchi R, Hirano S, Sudo T, Ohashi Y. Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01). *Lancet* 2016; **388**: 248-257 [PMID: 27265347 DOI: 10.1016/s0140-6736(16)30583-9]

56 **Riall TS**, Lillemoe KD. Underutilization of surgical resection in patients with localized pancreatic cancer. *Ann Surg* 2007; **246**: 181-182 [PMID: 17667494 DOI: 10.1097/SLA.0b013e31811eaa2c]

57 **Hartwig W**, Werner J, Jäger D, Debus J, Büchler MW. Improvement of surgical results for pancreatic cancer. *Lancet Oncol* 2013; **14**: e476-e485 [PMID: 24079875 DOI: 10.1016/s1470-2045(13)70172-4]

58 **Tempero MA**, Arnoletti JP, Behrman SW, Ben-Josef E, Benson AB, Casper ES, Cohen SJ, Czito B, Ellenhorn JD, Hawkins WG, Herman J, Hoffman JP, Ko A, Komanduri S, Koong A, Ma WW, Malafa MP, Merchant NB, Mulvihill SJ, Muscarella P, Nakakura EK, Obando J, Pitman MB, Sasson AR, Tally A, Thayer SP, Whiting S, Wolff RA, Wolpin BM, Freedman-Cass DA, Shead DA. Pancreatic Adenocarcinoma, version 2.2012: featured updates to the NCCN Guidelines. *J Natl Compr Canc Netw* 2012; **10**: 703-713 [PMID: 22679115]

59 **de Wilde RF**, Besselink MG, van der Tweel I, de Hingh IH, van Eijck CH, Dejong CH, Porte RJ, Gouma DJ, Busch OR, Molenaar IQ. Impact of nationwide centralization of pancreaticoduodenectomy on hospital mortality. *Br J Surg* 2012; **99**: 404-410 [PMID: 22237731 DOI: 10.1002/bjs.8664]

60 **Finks JF**, Osborne NH, Birkmeyer JD. Trends in hospital volume and operative mortality for high-risk surgery. *N Engl J Med* 2011; **364**: 2128-2137 [PMID: 21631325 DOI: 10.1056/NEJMsa1010705]

61 **Ducreux M**, Cuhna AS, Caramella C, Hollebecque A, Burtin P, Goéré D, Seufferlein T, Haustermans K, Van Laethem JL, Conroy T, Arnold D. Cancer of the pancreas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol* 2015; **26 Suppl 5**: v56-v68 [PMID: 26314780 DOI: 10.1093/annonc/mdv295]

62 **Hackert T**, Schneider L, Büchler MW. Current State of Vascular Resections in Pancreatic Cancer Surgery. *Gastroenterol Res Pract* 2015; **2015**: 120207 [PMID: 26609306 DOI: 10.1155/2015/120207]

63 **Kulemann B**, Hoeppner J, Wittel U, Glatz T, Keck T, Wellner UF, Bronsert P, Sick O, Hopt UT, Makowiec F, Riediger H. Perioperative and long-term outcome after standard pancreaticoduodenectomy, additional portal vein and multivisceral resection for pancreatic head cancer. *J Gastrointest Surg* 2015; **19**: 438-444 [PMID: 25567663 DOI: 10.1007/s11605-014-2725-8]

64 **Hartwig W**, Vollmer CM, Fingerhut A, Yeo CJ, Neoptolemos JP, Adham M, Andrén-Sandberg A, Asbun HJ, Bassi C, Bockhorn M, Charnley R, Conlon KC, Dervenis C, Fernandez-Cruz L, Friess H, Gouma DJ, Imrie CW, Lillemoe KD, Milićević MN, Montorsi M, Shrikhande SV, Vashist YK, Izbicki JR, Büchler MW. Extended pancreatectomy in pancreatic ductal adenocarcinoma: definition and consensus of the International Study Group for Pancreatic Surgery (ISGPS). *Surgery* 2014; **156**: 1-14 [PMID: 24856668 DOI: 10.1016/j.surg.2014.02.009]

65 **Schneider EB**, Ejaz A, Spolverato G, Hirose K, Makary MA, Wolfgang CL, Ahuja N, Weiss M, Pawlik TM. Hospital volume and patient outcomes in hepato-pancreatico-biliary surgery: is assessing differences in mortality enough? *J Gastrointest Surg* 2014; **18**: 2105-2115 [PMID: 25297443 DOI: 10.1007/s11605-014-2619-9]

66 **Spolverato G**, Ejaz A, Hyder O, Kim Y, Pawlik TM. Failure to rescue as a source of variation in hospital mortality after hepatic surgery. *Br J Surg* 2014; **101**: 836-846 [PMID: 24760705 DOI: 10.1002/bjs.9492]

67 **Amini N**, Spolverato G, Kim Y, Pawlik TM. Trends in Hospital Volume and Failure to Rescue for Pancreatic Surgery. *J Gastrointest Surg* 2015; **19**: 1581-1592 [PMID: 25794484 DOI: 10.1007/s11605-015-2800-9]

68 **van der Geest LG**, van Rijssen LB, Molenaar IQ, de Hingh IH, Groot Koerkamp B, Busch OR, Lemmens VE, Besselink MG. Volume-outcome relationships in pancreatoduodenectomy for cancer. *HPB (Oxford)* 2016; **18**: 317-324 [PMID: 27037200 DOI: 10.1016/j.hpb.2016.01.515]

69 **Labori KJ**, Katz MH, Tzeng CW, Bjørnbeth BA, Cvancarova M, Edwin B, Kure EH, Eide TJ, Dueland S, Buanes T, Gladhaug IP. Impact of early disease progression and surgical complications on adjuvant chemotherapy completion rates and survival in patients undergoing the surgery first approach for resectable pancreatic ductal adenocarcinoma - A population-based cohort study. *Acta Oncol* 2016; **55**: 265-277 [PMID: 26213211 DOI: 10.3109/0284186x.2015.1068445]

70 **Tzeng CW**, Tran Cao HS, Lee JE, Pisters PW, Varadhachary GR, Wolff RA, Abbruzzese JL, Crane CH, Evans DB, Wang H, Abbott DE, Vauthey JN, Aloia TA, Fleming JB, Katz MH. Treatment sequencing for resectable pancreatic cancer: influence of early metastases and surgical complications on multimodality therapy completion and survival. *J Gastrointest Surg* 2014; **18**: 16-24; discussion 24-5 [PMID: 24241967 DOI: 10.1007/s11605-013-2412-1]

71 **Halloran CM**, Platt K, Gerard A, Polydoros F, O'Reilly DA, Gomez D, Smith A, Neoptolemos JP, Soonwalla Z, Taylor M, Blazeby JM, Ghaneh P. PANasta Trial; Cattell Warren versus Blumgart techniques of panreatico-jejunostomy following pancreato-duodenectomy: Study protocol for a randomized controlled trial. *Trials* 2016; **17**: 30 [PMID: 26772736 DOI: 10.1186/s13063-015-1144-9]

72 **Katz MH**, Pisters PW, Evans DB, Sun CC, Lee JE, Fleming JB, Vauthey JN, Abdalla EK, Crane CH, Wolff RA, Varadhachary GR, Hwang RF. Borderline resectable pancreatic cancer: the importance of this emerging stage of disease. *J Am Coll Surg* 2008; **206**: 833-46; discussion 846-8 [PMID: 18471707 DOI: 10.1016/j.jamcollsurg.2007.12.020]

73 **Malafa MP**. Defining borderline resectable pancreatic cancer: emerging consensus for an old challenge. *J Natl Compr Canc Netw* 2015; **13**: 501-504 [PMID: 25964634]

74 **Roland CL**, Yang AD, Katz MH, Chatterjee D, Wang H, Lin H, Vauthey JN, Pisters PW, Varadhachary GR, Wolff RA, Crane CH, Lee JE, Fleming JB. Neoadjuvant therapy is associated with a reduced lymph node ratio in patients with potentially resectable pancreatic cancer. *Ann Surg Oncol* 2015; **22**: 1168-1175 [PMID: 25352267 DOI: 10.1245/s10434-014-4192-6]

75 **Roland CL**, Katz MH, Tzeng CW, Lin H, Varadhachary GR, Shroff R, Javle M, Fogelman D, Wolff RA, Vauthey JN, Crane CH, Lee JE, Fleming JB. The Addition of Postoperative Chemotherapy is Associated with Improved Survival in Patients with Pancreatic Cancer Treated with Preoperative Therapy. *Ann Surg Oncol* 2015; **22 Suppl 3**: S1221-S1228 [PMID: 26350371 DOI: 10.1245/s10434-015-4854-z]

76 **Werner J**, Combs SE, Springfeld C, Hartwig W, Hackert T, Büchler MW. Advanced-stage pancreatic cancer: therapy options. *Nat Rev Clin Oncol* 2013; **10**: 323-333 [PMID: 23629472 DOI: 10.1038/nrclinonc.2013.66]

77 **Yachida S**, Jones S, Bozic I, Antal T, Leary R, Fu B, Kamiyama M, Hruban RH, Eshleman JR, Nowak MA, Velculescu VE, Kinzler KW, Vogelstein B, Iacobuzio-Donahue CA. Distant metastasis occurs late during the genetic evolution of pancreatic cancer. *Nature* 2010; **467**: 1114-1117 [PMID: 20981102 DOI: 10.1038/nature09515]

78 **Gillen S**, Schuster T, Meyer Zum Büschenfelde C, Friess H, Kleeff J. Preoperative/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages. *PLoS Med* 2010; **7**: e1000267 [PMID: 20422030 DOI: 10.1371/journal.pmed.1000267]

79 **Tang K**, Lu W, Qin W, Wu Y. Neoadjuvant therapy for patients with borderline resectable pancreatic cancer: A systematic review and meta-analysis of response and resection percentages. *Pancreatology* 2016; **16**: 28-37 [PMID: 26687001 DOI: 10.1016/j.pan.2015.11.007]

80 **Lutfi W**, Talamonti MS, Kantor O, Wang CH, Liederbach E, Stocker SJ, Bentrem DJ, Roggin KK, Winchester DJ, Marsh R, Prinz RA, Baker MS. Perioperative chemotherapy is associated with a survival advantage in early stage adenocarcinoma of the pancreatic head. *Surgery* 2016; **160**: 714-724 [PMID: 27422328 DOI: 10.1016/j.surg.2016.05.029]

81 **Tsai S**, Evans DB. Therapeutic Advances in Localized Pancreatic Cancer. *JAMA Surg* 2016; **151**: 862-868 [PMID: 27276001 DOI: 10.1001/jamasurg.2016.1113]

82 **Bockhorn M**, Uzunoglu FG, Adham M, Imrie C, Milicevic M, Sandberg AA, Asbun HJ, Bassi C, Büchler M, Charnley RM, Conlon K, Cruz LF, Dervenis C, Fingerhutt A, Friess H, Gouma DJ, Hartwig W, Lillemoe KD, Montorsi M, Neoptolemos JP, Shrikhande SV, Takaori K, Traverso W, Vashist YK, Vollmer C, Yeo CJ, Izbicki JR. Borderline resectable pancreatic cancer: a consensus statement by the International Study Group of Pancreatic Surgery (ISGPS). *Surgery* 2014; **155**: 977-988 [PMID: 24856119 DOI: 10.1016/j.surg.2014.02.001]

83 **Asbun HJ**, Conlon K, Fernandez-Cruz L, Friess H, Shrikhande SV, Adham M, Bassi C, Bockhorn M, Büchler M, Charnley RM, Dervenis C, Fingerhutt A, Gouma DJ, Hartwig W, Imrie C, Izbicki JR, Lillemoe KD, Milicevic M, Montorsi M, Neoptolemos JP, Sandberg AA, Sarr M, Vollmer C, Yeo CJ, Traverso LW. When to perform a pancreatoduodenectomy in the absence of positive histology? A consensus statement by the International Study Group of Pancreatic Surgery. *Surgery* 2014; **155**: 887-892 [PMID: 24661765 DOI: 10.1016/j.surg.2013.12.032]

84 **Nordby T**, Ikdahl T, Bowitz Lothe IM, Fagerland MW, Heiberg T, Hauge T, Labori KJ, Buanes T. Improved survival and quality of life in patients undergoing R1 pancreatic resection compared to patients with locally advanced unresectable pancreatic adenocarcinoma. *Pancreatology* 2013; **13**: 180-185 [PMID: 23561977 DOI: 10.1016/j.pan.2013.01.003]

85 **Westgaard A**, Tafjord S, Farstad IN, Cvancarova M, Eide TJ, Mathisen O, Clausen OP, Gladhaug IP. Pancreatobiliary versus intestinal histologic type of differentiation is an independent prognostic factor in resected periampullary adenocarcinoma. *BMC Cancer* 2008; **8**: 170 [PMID: 18547417 DOI: 10.1186/1471-2407-8-170]

86 **Westgaard A**, Pomianowska E, Clausen OP, Gladhaug IP. Intestinal-type and pancreatobiliary-type adenocarcinomas: how does ampullary carcinoma differ from other periampullary malignancies? *Ann Surg Oncol* 2013; **20**: 430-439 [PMID: 22956064 DOI: 10.1245/s10434-012-2603-0]

87 **Poultsides GA**, Huang LC, Cameron JL, Tuli R, Lan L, Hruban RH, Pawlik TM, Herman JM, Edil BH, Ahuja N, Choti MA, Wolfgang CL, Schulick RD. Duodenal adenocarcinoma: clinicopathologic analysis and implications for treatment. *Ann Surg Oncol* 2012; **19**: 1928-1935 [PMID: 22167476 DOI: 10.1245/s10434-011-2168-3]

88 **Albores-Saavedra J**, Schwartz AM, Batich K, Henson DE. Cancers of the ampulla of vater: demographics, morphology, and survival based on 5,625 cases from the SEER program. *J Surg Oncol* 2009; **100**: 598-605 [PMID: 19697352 DOI: 10.1002/jso.21374]

89 **Courtin-Tanguy L**, Rayar M, Bergeat D, Merdrignac A, Harnoy Y, Boudjema K, Meunier B, Sulpice L. The true prognosis of resected distal cholangiocarcinoma. *J Surg Oncol* 2016; **113**: 575-580 [PMID: 26776934 DOI: 10.1002/jso.24165]

90 **Onkendi EO**, Boostrom SY, Sarr MG, Farnell MB, Nagorney DM, Donohue JH, Kendrick ML, Reid-Lombardo KM, Harmsen WS, Que FG. 15-year experience with surgical treatment of duodenal carcinoma: a comparison of periampullary and extra-ampullary duodenal carcinomas. *J Gastrointest Surg* 2012; **16**: 682-691 [PMID: 22350721 DOI: 10.1007/s11605-011-1808-z]

91 **Buchbjerg T**, Fristrup C, Mortensen MB. The incidence and prognosis of true duodenal carcinomas. *Surg Oncol* 2015; **24**: 110-116 [PMID: 25936244 DOI: 10.1016/j.suronc.2015.04.004]

92 **Pomianowska E**, Grzyb K, Westgaard A, Clausen OP, Gladhaug IP. Reclassification of tumour origin in resected periampullary adenocarcinomas reveals underestimation of distal bile duct cancer. *Eur J Surg Oncol* 2012; **38**: 1043-1050 [PMID: 22883964 DOI: 10.1016/j.ejso.2012.07.113]

93 **Schiergens TS**, Reu S, Neumann J, Renz BW, Niess H, Boeck S, Heinemann V, Bruns CJ, Jauch KW, Kleespies A. Histomorphologic and molecular phenotypes predict gemcitabine response and overall survival in adenocarcinoma of the ampulla of Vater. *Surgery* 2015; **158**: 151-161 [PMID: 25819575 DOI: 10.1016/j.surg.2015.02.001]

94 **Showalter TN**, Zhan T, Anne PR, Chervoneva I, Mitchell EP, Yeo CJ, Rosato EL, Kennedy EP, Berger AC. The influence of prognostic factors and adjuvant chemoradiation on survival after pancreaticoduodenectomy for ampullary carcinoma. *J Gastrointest Surg* 2011; **15**: 1411-1416 [PMID: 21523621 DOI: 10.1007/s11605-011-1518-6]

95 **Neoptolemos JP**, Moore MJ, Cox TF, Valle JW, Palmer DH, McDonald AC, Carter R, Tebbutt NC, Dervenis C, Smith D, Glimelius B, Charnley RM, Lacaine F, Scarfe AG, Middleton MR, Anthoney A, Ghaneh P, Halloran CM, Lerch MM, Oláh A, Rawcliffe CL, Verbeke CS, Campbell F, Büchler MW. Effect of adjuvant chemotherapy with fluorouracil plus folinic acid or gemcitabine *vs* observation on survival in patients with resected periampullary adenocarcinoma: the ESPAC-3 periampullary cancer randomized trial. *JAMA* 2012; **308**: 147-156 [PMID: 22782416 DOI: 10.1001/jama.2012.7352]

96 **Bailey P**, Chang DK, Nones K, Johns AL, Patch AM, Gingras MC, Miller DK, Christ AN, Bruxner TJ, Quinn MC, Nourse C, Murtaugh LC, Harliwong I, Idrisoglu S, Manning S, Nourbakhsh E, Wani S, Fink L, Holmes O, Chin V, Anderson MJ, Kazakoff S, Leonard C, Newell F, Waddell N, Wood S, Xu Q, Wilson PJ, Cloonan N, Kassahn KS, Taylor D, Quek K, Robertson A, Pantano L, Mincarelli L, Sanchez LN, Evers L, Wu J, Pinese M, Cowley MJ, Jones MD, Colvin EK, Nagrial AM, Humphrey ES, Chantrill LA, Mawson A, Humphris J, Chou A, Pajic M, Scarlett CJ, Pinho AV, Giry-Laterriere M, Rooman I, Samra JS, Kench JG, Lovell JA, Merrett ND, Toon CW, Epari K, Nguyen NQ, Barbour A, Zeps N, Moran-Jones K, Jamieson NB, Graham JS, Duthie F, Oien K, Hair J, Grützmann R, Maitra A, Iacobuzio-Donahue CA, Wolfgang CL, Morgan RA, Lawlor RT, Corbo V, Bassi C, Rusev B, Capelli P, Salvia R, Tortora G, Mukhopadhyay D, Petersen GM, Munzy DM, Fisher WE, Karim SA, Eshleman JR, Hruban RH, Pilarsky C, Morton JP, Sansom OJ, Scarpa A, Musgrove EA, Bailey UM, Hofmann O, Sutherland RL, Wheeler DA, Gill AJ, Gibbs RA, Pearson JV, Waddell N, Biankin AV, Grimmond SM. Genomic analyses identify molecular subtypes of pancreatic cancer. *Nature* 2016; **531**: 47-52 [PMID: 26909576 DOI: 10.1038/nature16965]

97 **Shrikhande SV**, Kleeff J, Reiser C, Weitz J, Hinz U, Esposito I, Schmidt J, Friess H, Büchler MW. Pancreatic resection for M1 pancreatic ductal adenocarcinoma. *Ann Surg Oncol* 2007; **14**: 118-127 [PMID: 17066229 DOI: 10.1245/s10434-006-9131-8]

98 **de Jong MC**, Tsai S, Cameron JL, Wolfgang CL, Hirose K, van Vledder MG, Eckhauser F, Herman JM, Edil BH, Choti MA, Schulick RD, Pawlik TM. Safety and efficacy of curative intent surgery for peri-ampullary liver metastasis. *J Surg Oncol* 2010; **102**: 256-263 [PMID: 20740584 DOI: 10.1002/jso.21610]

99 **Crippa S**, Bittoni A, Sebastiani E, Partelli S, Zanon S, Lanese A, Andrikou K, Muffatti F, Balzano G, Reni M, Cascinu S, Falconi M. Is there a role for surgical resection in patients with pancreatic cancer with liver metastases responding to chemotherapy? *Eur J Surg Oncol* 2016; **42**: 1533-1539 [PMID: 27423449 DOI: 10.1016/j.ejso.2016.06.398]

100 **Heiberg T**, Nordby T, Kvien TK, Buanes T. Development and preliminary validation of the pancreatic cancer disease impact score. *Support Care Cancer* 2013; **21**: 1677-1684 [PMID: 23314652 DOI: 10.1007/s00520-012-1713-3]

**P-Reviewer:** Chen YC, Neri V, Takahashi H **S-Editor:** Yu J **L-Editor:** **E-Editor:**

**Specialty type:** Gastroenterology and hepatology

**Country of origin:** Norway

**Peer-review report classification**

Grade A (Excellent): A

Grade B (Very good): B

Grade C (Good): C

Grade D (Fair): 0

Grade E (Poor): 0

**Table 1 Important clinical trials in metastatic pancreatic ductal adenocarcinoma**

|  |  |  |  |
| --- | --- | --- | --- |
| **Ref.** | **Year published** | **Investigated drugs** | **Clinical outcome** |
|  |  |  | OS | ORR |
| Burris *et al*[[39](#_ENREF_39)] | 1997 | Gemcitabine *vs* 5-FU | 5.65 mo *vs* 4.4 mo | 5.4% *vs* 0% |
| Ueno *et al*[[40](#_ENREF_40)] | 2005 | S-1 (gimeril and oteracil) | 5.6 mo | 21.1% |
| Moore *et al*[[41](#_ENREF_41)] | 2007 | Gemcitabine *vs* erlotinib | 5.91 mo *vs* 6.24 mo | 8.0% *vs* 8,6% |
| Conroy *et al*[[42](#_ENREF_42)] | 2011 | Gemcitabine *vs* Oxaliplatin + irinotecan + leucoverin + 5-FU (FOLFIRINOX) | 6.8 mo *vs* 11.1 mo | 9.4% *vs* 31.6% |
| Von Hoff *et al*[[43](#_ENREF_43)] | 2013 | Gemcitabine *vs* gemcitabine + nab-paclitaxel | 6.7 mo *vs* 8.5 mo | 7% *vs* 23 % |

OS: Overall survival; ORR: Overall response rate.

**Table 2 Important clinical trials evaluating adjuvant chemotherapy in pancreatic ductal adenocarcinoma**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Ref.** | **Year published** | **Investigated drugs** | **Number of patients** | **Clinical outcome** |
|  |  |  |  | Median survival(mo) | 5-year survival(%) |
| Neoptolemos *et al*[[19](#_ENREF_19),[52](#_ENREF_52)] (ESPAC 1)  | 2001and2004 | 5-FU/FA *vs*No chemotherapy | 149143 | 20.115.5 | 218 |
| Oettle *et al* [[53](#_ENREF_53)] | 2007 | Gemcitabine *vs* No chemotherapy | 179175 | 22.120.2 | 22.511.5 |
| Neoptolemos *et al*[[20](#_ENREF_20)](ESPAC 3)  | 2010 | Gemcitabine *vs*5-FU/FA *vs* | 539551 | 23.623.0 | 17.515.9 |
| Neoptolemos *et al*[[20](file:///C%3A%5CUsers%5Cbaishideng-2014%5CDesktop%5Crevised-jyu%5C29469%5C29469-Review.docx#_ENREF_20)](ESPAC 4) | 2016 | Gemcitabine *vs*Gemcitabine +Capecitabine | 366364 | 25.528.0 | 16.328.8 |
| Uesaka *et al*[[55](#_ENREF_55)] | 2016 | Gemcitabine *vs*S1 | 193192 | 24.546.5 | 24.444.1 |

5-FU: 5-Fluorouraci.